NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CHRS

Coherus Oncology Inc

Jun 23 • 02:17PM ET

0.7287

Dollar change -0.0185
Percentage change -2.48	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD ABBV VRTX REGN BIIB INCY BMRN NBIX EXEL

| Held by: VTI IWM VXF IWN VTWO SCHA VHT IWO IWC PRFZ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.13	Insider Own	9.07%	Shs Outstand	115.91M	Perf Week	-4.33%
Market Cap	84.49M	Forward P/E	-	EPS next Y	-0.82	Insider Trans	-0.94%	Shs Float	105.41M	Perf Month	-5.72%
Enterprise Value	301.58M	PEG	-	EPS next Q	-0.26	Inst Own	51.07%	Short Float	30.86%	Perf Quarter	-29.25%
Income	-130.94M	P/S	0.43	EPS this Y	-626.69%	Inst Trans	-6.28%	Short Ratio	19.91	Perf Half Y	-57.39%
Sales	197.50M	P/B	-	EPS next Y	37.57%	ROA	-21.46%	Short Interest	32.53M	Perf YTD	-47.20%
Book/sh	-1.58	P/C	1.03	EPS next 5Y	-	ROE	-	52W High	2.43 -70.01%	Perf Year	-55.02%
Cash/sh	0.71	P/FCF	168.97	EPS past 3/5Y	- -27.36%	ROIC	-114.62%	52W Low	0.66 10.36%	Perf 3Y	-87.83%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-6.50% -5.60%	Gross Margin	54.21%	Volatility	3.13% 2.73%	Perf 5Y	-95.76%
Dividend TTM	-	EV/Sales	1.53	EPS Y/Y TTM	-62.19%	Oper. Margin	-54.64%	ATR (14)	0.05	Perf 10Y	-97.26%
Dividend Ex-Date	-	Quick Ratio	1.20	Sales Y/Y TTM	-34.58%	Profit Margin	-66.30%	RSI (14)	37.99	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.22	EPS Q/Q	-159.59%	SMA20	-7.17%	Beta	0.88	Target Price	4.68
Payout	0.00%	Debt/Eq	-	Sales Q/Q	-90.14%	SMA50	-17.45%	Rel Volume	0.68	Prev Close	0.75
Employees	228	LT Debt/Eq	-	Earnings	May 12 AMC	SMA200	-31.45%	Avg Volume	1.63M	Price	0.73
IPO	Nov 06, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-37.86% -86.10%	Trades		Volume	835,700	Change	-2.48%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-16-24	Downgrade	UBS	Buy → Neutral	$4 → $1.50
Nov-17-23	Initiated	Robert W. Baird	Outperform	$11
Nov-08-23	Downgrade	Maxim Group	Buy → Hold
Jul-24-23	Initiated	Citigroup	Buy	$12
May-01-23	Initiated	Truist	Buy	$24
Mar-28-23	Upgrade	UBS	Neutral → Buy	$11
Jun-14-22	Initiated	UBS	Neutral	$7
Mar-07-22	Downgrade	JP Morgan	Overweight → Neutral	$15
Jul-16-20	Initiated	BofA Securities	Neutral	$20
Apr-17-20	Initiated	SunTrust	Buy	$26
Aug-13-19	Initiated	Mizuho	Buy
Aug-02-19	Reiterated	Maxim Group	Buy	$25 → $27
Aug-02-19	Reiterated	H.C. Wainwright	Buy	$28 → $29
Jun-11-19	Initiated	Barclays	Overweight	$30
May-07-19	Initiated	H.C. Wainwright	Buy	$28
Aug-28-18	Initiated	H.C. Wainwright	Buy	$28
Mar-09-18	Reiterated	Maxim Group	Buy	$20 → $15
Aug-08-17	Reiterated	JP Morgan	Overweight	$32 → $25
Jun-13-17	Reiterated	Maxim Group	Buy	$44 → $40
May-05-17	Initiated	BMO Capital Markets	Outperform	$54

Show Previous Ratings

Jun-06-25 04:29PM	Coherus BioSciences, Inc. (CHRS): A Bull Case Theory (Insider Monkey)
May-30-25 08:00AM	Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics (GlobeNewswire)
May-27-25 08:30AM	Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI (toripalimab-tpzi) (GlobeNewswire)
May-13-25 02:22PM	Q1 2025 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents) -19.11%
03:10AM	Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ... (GuruFocus.com)
05:30PM	Loading…
May-12-25 05:30PM	Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.30%
04:27PM	Coherus BioSciences: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-09-25 09:45AM	What To Expect From Coherus BioSciences Inc (CHRS) Q1 2025 Earnings (GuruFocus.com)
May-05-25 04:01PM	Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 (GlobeNewswire) -7.27% -8.83%
May-01-25 05:04PM	Coherus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-28-25 10:10AM	Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 (GlobeNewswire)
Apr-17-25 05:53AM	Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs (Seeking Alpha) +10.89%
Apr-15-25 09:44AM	Coherus divests Udenyca franchise to Intas for up to $558.4m (Pharmaceutical Technology) +8.76%
Apr-14-25 08:00AM	Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA Franchise (GlobeNewswire) +16.59%
08:00AM	Loading…
Apr-01-25 08:00AM	Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes (GlobeNewswire)
Mar-25-25 04:30PM	Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -5.81%
Mar-21-25 07:10AM	Lazard Enhanced Opportunities Portfolio Q4 2024 Commentary (SeekingAlpha) +8.83%
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-12-25 03:23PM	Coherus BioSciences, Inc. (CHRS): A Bull Case Theory (Insider Monkey) -6.67%
Mar-11-25 01:46PM	Q4 2024 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)
03:02AM	Coherus BioSciences Inc (CHRS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Mar-10-25 04:32PM	Coherus BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
04:12PM	Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-07-25 07:06AM	What To Expect From Coherus BioSciences Inc (CHRS) Q4 2024 Earnings (GuruFocus.com)
Mar-03-25 08:30AM	Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025 (GlobeNewswire) -9.46%
Feb-24-25 09:08AM	Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire) +7.48%
Feb-12-25 08:39AM	Coherus BioSciences, Inc. (CHRS): A Bull Case Theory (Insider Monkey)
Jan-22-25 07:00AM	Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 (GlobeNewswire)
Jan-08-25 08:00AM	Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:30AM	Loading…
Dec-18-24 08:30AM	Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 (GlobeNewswire) -8.19%
Dec-03-24 07:00AM	Coherus Announces Agreement to Divest UDENYCA Franchise for up to $558 million to Intas Pharmaceuticals Ltd. (GlobeNewswire) +24.82%
06:06AM	Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M (BioPharma Dive)
Nov-27-24 04:01PM	Coherus Management to Participate in the 2024 Citi Global Healthcare Conference (GlobeNewswire)
Nov-07-24 01:09PM	Q3 2024 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents) +13.29%
02:26AM	Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Nov-06-24 05:15PM	Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:11PM	Coherus BioSciences: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 08:08AM	Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com) +9.10%
Oct-30-24 04:20PM	Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-09-24 06:01PM	Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Sep-28-24 07:24AM	Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-25-24 11:28AM	Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges (Insider Monkey)
Aug-08-24 05:50PM	Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +10.85%
04:45PM	Coherus BioSciences: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-24 09:00AM	Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire) -7.14%
Jun-28-24 07:49AM	PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar (BioPharma Dive)
Jun-27-24 08:26AM	Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction (GlobeNewswire)
Jun-05-24 09:00AM	Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors (GlobeNewswire)
May-30-24 09:00AM	Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 05:51PM	Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
09:00AM	Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA (GlobeNewswire)
May-13-24 09:23AM	Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating (MT Newswires) +10.00%
May-10-24 04:45PM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2024 Earnings Call Transcript (Insider Monkey) -10.38%
May-09-24 05:15PM	Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:12PM	Coherus BioSciences: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:30AM	Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan (GlobeNewswire)
May-08-24 09:00AM	Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer (GlobeNewswire)
May-01-24 04:30PM	Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire) +5.10% +5.34%
Apr-24-24 10:02AM	Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.34%
Apr-08-24 08:30AM	Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting (GlobeNewswire)
Mar-16-24 03:35PM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 06:28PM	Why Coherus Biosciences Stock Tumbled on Thursday (Motley Fool) -5.65%
07:15AM	Q4 2023 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 05:32PM	Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ... (GuruFocus.com)
04:13PM	Coherus BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update (GlobeNewswire)
Mar-05-24 04:01PM	Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 (GlobeNewswire)
Mar-04-24 01:00AM	Coherus Completes Divestiture of Ophthalmology Franchise (GlobeNewswire) -5.81%
Feb-23-24 05:33PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire)
Feb-21-24 08:30AM	Coherus Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv (GlobeNewswire)
Feb-06-24 05:16PM	Why Coherus BioSciences Stock Jumped Today (Motley Fool) +14.85%
Feb-05-24 08:00AM	Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP (GlobeNewswire)
Jan-23-24 11:37AM	Why Coherus BioSciences Stock Is Sinking Today (Motley Fool) -6.98%
Jan-22-24 03:41PM	Why Coherus Biosciences Popped Today (Motley Fool) +5.74%
08:38AM	Why Is Coherus BioSciences (CHRS) Stock Up 17% Today? (InvestorPlace)
01:15AM	Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal (GlobeNewswire)
Jan-18-24 04:05PM	Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium (GlobeNewswire)
Jan-12-24 03:06AM	Here's Why Aristotle Small Cap Equity Strategy Sold Coherus BioSciences (CHRS) (Insider Monkey)
Jan-04-24 08:00AM	INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI (toripalimab-tpzi) (PR Newswire)
Jan-03-24 09:00AM	Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-24 08:29AM	Coherus Announces U.S. Launch of LOQTORZI (GlobeNewswire) -5.71%
Dec-28-23 03:45PM	Why Coherus BioSciences Stock Jumped Today (Motley Fool) +20.45%
11:07AM	Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody (Zacks)
Dec-27-23 05:07PM	These Stocks Moved the Most Today: Tesla, Apple, Coinbase, MicroStrategy, Iovance, NetEase, and More (Barrons.com) +23.39%
01:06PM	These Stocks Are Moving the Most Today: Tesla, Apple, Coinbase, MicroStrategy, Iovance, NetEase, and More (Barrons.com)
Dec-26-23 04:01PM	Coherus Announces FDA Approval of UDENYCA ONBODY , a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv (GlobeNewswire) +7.92%
Dec-24-23 09:45AM	2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street (Motley Fool)
Dec-22-23 05:00PM	Coherus BioSciences Announces New Employment Inducement Grants (GlobeNewswire) +7.92%
Dec-11-23 08:30AM	Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx (GlobeNewswire)
Dec-07-23 05:55PM	Coherus BioSciences Announces CFO Transition Plans (GlobeNewswire)
Dec-06-23 04:00AM	Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress (GlobeNewswire)
Nov-28-23 11:16AM	Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association (GlobeNewswire) +8.76%
Nov-10-23 03:15PM	Why Coherus BioSciences Was Plummeting This Week (Motley Fool)
Nov-07-23 03:37PM	Why Coherus Biosciences Stock Dropped Today (Motley Fool) -30.23%
10:46AM	Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:19AM	Q3 2023 Coherus BioSciences Inc Earnings Call (Thomson Reuters StreetEvents)

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wahlstrom Mats	Director	May 23 '25	Sale	0.74	99,988	73,881	0	May 28 05:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CHRS

Coherus Oncology Inc

Upgrade your FINVIZ experience